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The Japanese regulatory framework for pharmaceuticals and medical devices has recently been reex-
amined and the revised Pharmaceutical Affairs Law, which has been renamed the Pharmaceuticals,
Medical Devices and Other Therapeutic Products Act, was developed in 2013 and implemented in
November 2014. In the revised Act, regenerative medical products are newly categorized and indepen-
dent from conventional pharmaceuticals and medical devices. This enables these products to be
reviewed more appropriately and allows for conditional/time-limited marketing authorization.
Following the implementation of the new Act, the Good, Gene Cell and Tissue Manufacturing Practice
was established to address the different requirements and concepts for appropriate research and
development of regenerative medical products. Based on these changes to the regulatory framework for
regenerative medical products in Japan, this article aims to examine how this framework could be uti-
lized as an appropriate system to develop innovative regenerative medicine.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Regenerative medicine is a method to treat diseased or damaged
organs using stem or somatic cells and tissues. The method enables
the treatment of intractable diseases or injuries, and efforts to
develop innovative techniques of regenerative medicine have
increased considerably in recent years [1]. Since 2011, the regula-
tory frameworks for pharmaceuticals and medical devices in Japan
have been reexamined and the revised Pharmaceutical Affairs Law,
which was renamed the Pharmaceuticals, Medical Devices andl Devices and Other Thera-
ine Promoting Act; MHLW,
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ative Medicine. Production and hoOther Therapeutic Products Act (PMD Act), was developed in
November 2013 and implemented in November 2014 [2,3]. Based
on this new legal framework, Japan will have the potential to
become a prime venue for international medical researchers and
industries [4]. This article aims to examine how this framework
could be utilized as an appropriate system to develop innovative
regenerative medicine.
1.1. The new framework for regenerative medical products and the
PMD Act
The ﬁeld of regenerative medicine using regenerative medical
products has become amajor focus of global research. Regenerative
medicine aims to regain the function of organs damaged by illness
or injury and increases the possibility of ﬁnding a treatment for
intractable diseases. Therefore, promoting regenerative medicine
can be expected to become a new focus for patients who suffer from
incurable diseases and injuries. However, because regenerative
medicine utilizes ingredients derived from living cells and tissues,
it carries a risk of bacterial or viral infection and tumorigenicity. It is
therefore imperative that sufﬁcient safety measures are established
in parallel with the promotion of regenerative medicine. As part ofsting by Elsevier B.V. All rights reserved.
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Cabinet Decision), the reexamination of a special expedited
reviewing system for regenerative medical products was initiated.
In parallel with this emergency policy, the Regenerative Medicine
Promoting (RMP) Act was established. This Act deﬁnes the re-
sponsibilities of the government and citizens in Japan to utilize
regenerative medicine, and a scheme to enable the rapid and safe
clinical application of regenerative medicine was enacted by the
Diet, the national legislature of Japan, on April 26, 2013 [5]. The
RMP Act aims to comprehensively promote the use of regenerative
medicine by ensuring its safety. Following the introduction of this
Act, the government submitted the PMD Act, which is the revised
version of the Pharmaceutical Affairs Law [2,6].
As the ﬁrst change to the PMD Act, regenerative medical prod-
ucts related to regenerative medicine or gene therapy were newly
deﬁned. Regenerative medical products fall into two groups: (1)
products processed from the cells of a human or animal, with the
purpose to reconstruct, repair, or reform the physical structure of a
human or animal, or to treat or prevent the disease of a human or
animal, and (2) products that are introduced into the cells of a
human or animal to promote the development of a gene in the body
to treat illness of a human or animal. In addition, the Government
Ordinance of the PMD Act lists the categories of the products [7].
Human cell processing products include the following: (1) human
somatic cell processing products, (2) human somatic stem cell
processing products, (3) human embryonic stem cell processing
products, and (4) human artiﬁcial pluripotent cell processing
products. Gene therapy products include the following: (1) prod-
ucts derived from plasmid vectors, (2) products derived from virus
vectors, and (3) gene expression treatment products (quality to
advocate to previous two is excluded). Furthermore, in Notice no. 5
issued by the Director for Medical Devices and Regenerative
Products Review, Pharmaceutical and Food Safety Bureau, Ministry
of Health, Labour and Welfare (MHLW; August 12, 2014) [8], “pro-
cessing” is deﬁned as the artiﬁcial expansion/differentiation of
cells, establishment of a cell line, chemical treatment to activate
cells or tissues, modiﬁcation of biological characteristics, combi-
nation with non-cell/tissue components, and genetic modiﬁcation
of cells, cells for non-homologous use, all of which are conducted
for the purpose of treatment of diseases, or the repair or recon-
struction of tissues. “Processing” does not include the following
operations: separation and cutting of tissues, isolation of speciﬁc
cells (except for isolation following biological/chemical treat-
ments), treatment with antibiotics, washing, sterilization by
gamma ray, freezing, thawing (but not using cells for the purpose
intended to gain different structure and function from their original
cells). Examples of products that are not considered as regenerative
medical products include human red blood cell, human platelets,
fresh frozen plasma, blood plasma fractions, hematopoietic stem
cells grafts, fertilized embryos and gametes for reproduction
assistance medical care, placental extract (placental tissue), human
amnion, human endocranium, bioprosthetic valves, high mud gel
for wounds, dental plates, bone cement, artiﬁcial joints, artiﬁcial
vessels, cell stock solutions, attenuated live vaccines published by a
Standard of Biological Products [9], antisense oligonucleotides,
nucleic acid derivatives, ribozymes, and aptamers.
The second major change to the PMD Act is described below.
Because regenerative medical products use human/animal living
cells, which have heterogeneous qualities, long periods of time are
required to collect data and evaluate the effectiveness of treatment.
Therefore, a conditional/time-limited approval system was estab-
lished to facilitate the early clinical application of regenerative
medical products. This system enables the effectiveness of products
to be estimated early based on constant updates from the limited
numbers of cases treated. Acute side effects can be identiﬁed fromshort-term investigations, and the long-term safety is evaluated in
the post-marketing surveillance of a registry of all patients, which
is scheduled to be in place in 2015. The registry of all patients
treated with regenerative medical products is to be initially
controlled by the Pharmaceuticals and Medical Devices Agency
(PMDA), which is supported by the MHLW.
To further ensure the maintenance of safety measures, it is
clearly stated that doctors should provide patients with a thorough
explanation of all procedures and should obtain prior informed
consent. Doctors are also obliged to keep complete records on the
use of regenerative medical products. In addition, regenerative
medical products are to be included under the umbrella of the
Relief Services for Adverse Health Effects.
A further revision was the generation of a new standard (Good,
Gene, Cellular and Tissue-based Products Manufacturing Practice;
GCTP) for manufacturing management and quality control in the
industry to secure the quality and safety of the products [10]. In
addition, while it was previously forbidden to collect blood from
humans for manufacturing products other than blood and plasma
products, the new Act enables industry or hospitals to produce
regenerative medical products using blood collected from humans
as an ingredient.
1.2. New points for consideration in developing regenerative
medical products
For the appropriate development of regenerative medical
products, it is important to consider quality, safety, and efﬁcacy.
First, the following points should be considered to evaluate the
quality of the products [11]. The management of ingredients must
be appropriate, and the quality of the ingredients must meet the
Minimum Requirements for Biological Ingredients [12]. However, it
may be difﬁcult to determine whether the characteristic analysis of
a product is sufﬁcient. For example, it is important to ensure that
there has been appropriate conﬁrmation and quantitative evalua-
tion of selected or rejected cells, that eligibility tests of selected
cells have been conducted, that the proliferation properties of cells
are determined, and that the kind and quantity of impurities
derived from the process of manufacture are reasonable. In addi-
tion, for regulatory inspection, process validation/veriﬁcation dur-
ing the manufacturing process and quality control should be
performed appropriately based on the GCTP standard. For example,
it may be important to consider whether the evaluation of the
process to remove impurities, the examination of the quantity of
remaining impurities, the examination of the constitution of cell
class before and after the differentiation of cells, and the variety of
cell characteristics, are performed appropriately. The speciﬁcation
of the ﬁnal product must also be considered. For example, the
speciﬁcation depends on cell counts, cell survival rates, tests of
purity and sterility, mycoplasmal negation tests, titre examination,
and dynamic compliance tests.
The major aim of the GCTP standard is to set an appropriate
quality target to continuously monitor and improve the process
based on the control and acceptance of risk for each product in
terms of manufacturing facilities and quality management systems
[10]. It is necessary to establish quality management systems based
on the documentation of each step in the production process. The
control of sterility is a particular challenge in the production of
regenerative medical products. Because regenerative medical
products are derived from living cells and tissues, it is difﬁcult to
sterilize ingredients before and during the manufacturing process.
Contamination can occur during themanufacturing process and the
contaminated cells can proliferate. A standard for controlling bio-
burden remains to be established. Therefore, it is necessary to
consider the risk of contamination and the appropriate standard to
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medical product, the production facility, and the manufacturing
process.
Second, the following points are important considerations in
terms of safety in non-clinical investigations of regenerative med-
ical products [13]. The clinical applications of cellular and tissue
based products are diverse and it is difﬁcult to describe a standard
required evaluation of these products. Therefore, the products
should be evaluated on a case-by-case basis, depending on the
characteristics of individual products. For example, in in-
vestigations of effectiveness and performance, it should be
considered whether prospective effects such as the expression of
function and the durability of action are evaluable or not. In addi-
tion, to ensure safe non-clinical investigations, it is important to
consider risks based on the characteristics and the usage of the
product.
In terms of the clinical evaluation of regenerative medical
products, important points can be highlighted from reviews of
products already approved in Japan. In the clinical trial of a cultured
skin product (Japan Tissue Engineering Co., Ltd.) [14], two patients
with serious burns (Burn Index 30e90%) were included. One dis-
played 100% epidermization and the other displayed 50% epi-
dermization. There were no serious adverse events. The product
was ﬁnally approved for limited use in serious burn patients
because the beneﬁts for such patients were considered to be su-
perior to the potential unknown risks. This example raises the
important point that the conditions of approval can be changed
based on the risk/beneﬁt balance for the individual product, the
clinical application (especially related to the seriousness of disease
and the existence of alternative treatments), and the unexpected
risks, in particular, infection.
The efﬁcacy of a cultured cartilage product (Japan Tissue Engi-
neering Co., Ltd.) was investigated in a non-controlled, non-ran-
domized, non-blinded clinical trial. The product was transplanted
in 32 cases; 20 cases of traumatic cartilage deﬁciencies, six cases of
osteochondritis dissecans, and six cases of osteoarthritis [15]. In 23
of the 24 evaluable cases, clinical manifestations improved and
there were no serious adverse events related to the product.
However, meaningful evaluation was difﬁcult because of the non-
controlled, non-randomized, non-blinded study design, and
different diseases included. Reanalysis was performed only for
cases of cartilage deﬁciencies of more than 4 cm2. The product was
ﬁnally approved under post-marketing surveillance of all cases
based on the clinical beneﬁt for intractable injuries. This case
demonstrates that even non-controlled, non-randomized, non-
blinded trials may contribute to clinical data for marketing
approval. However, the clinical position and risk-beneﬁt balance
must be considered.
2. Discussion
In the development of regenerative medical products, there are
different problems to those faced in the development of conven-
tional pharmaceuticals and medical devices. Use of the products
often involves speciﬁc techniques for transplantation and collec-
tion, and the level of experience of medical institutes and individual
practitioners may affect the results of clinical trials. In addition,
because regenerative medical products are generally used to treat
intractable diseases or injuries it is difﬁcult to perform major ran-
domized clinical trials. Furthermore, the quality of products is more
heterogeneous compared with other chemical or biological prod-
ucts because the products involve living cells or tissues and the
quality of ingredients can vary according to the donor. The products
carry greater risks of infection, tumorigenicity, and immune re-
actions than conventional pharmaceuticals. Therefore,conventional development procedures and methods of regulatory
review may not be suitable for regenerative medical products. The
Japanese Government hasmoved tomake Japan an attractive venue
for researchers and sponsors based on its strategy for medical
innovation.With this aim inmind, the new category of regenerative
medical products and the system of conditional/time-limited
authorization was established in the PMD Act [1].
The conditional/time-limited authorization for regenerative
medical products is a type of adaptive licensing [16], which is
deﬁned as a prospectively planned, ﬂexible approach to the regu-
lation of drugs and biologics. In the present situation, the costs of
developing pharmaceuticals and medical devices have been
increasing, and the development of regenerative medical products
may involve additional costs because of the background issues
discussed above. Adaptive licensing is intended to decrease the cost
of incremental gains in health beneﬁts within an environment of
strained budgets. This concept is adopted in marketing approval for
regenerative medical products and is also expected to decrease the
cost of development.
For conditional/time-limited authorization of regenerative
medical products, the initial level of clinical evidence may be sug-
gested in some points referred from the concept of adaptive
licensing [17]. From investigators point of view, the surrogate
endpoint, which is not fully validated, will expected to be accept-
able in some situations andmore enriched patients can be included
in the trials. These points are sometimes acceptable in present
clinical trials for cancer or orphan diseases, but the effectiveness of
regenerative medical products is so varied that it is more difﬁcult to
determine the true clinical endpoints and appropriate inclusion
criteria. The problem of statistics is more serious. Because clinical
trials for regenerative medical products often have few cases and
the data represents a wide variation in cases and responses,
determining the appropriate statistical analysis is particularly
challenging. From investigators point of view, it could be appro-
priate to apply wider signiﬁcance levels than that used in con-
ventional trials, particularly in the initial review. In some special
cases such as intractable diseases or diseases with no alternative
treatments, single-arm, observational studies utilizing the registry
of the natural course of disease, or exploratory trials, will also ex-
pected to become pivotal for initial reviews. Even in these trials,
acute adverse events can be identiﬁed, and data on rare and
difﬁcult-to-detect adverse events have to be collected and re-
reviewed through post-marketing surveillance with the registry.
Some points about the appropriate management of conditional/
time-limited authorization under the aforementioned conditions
should be considered. First, the valid and feasible management of a
post-marketing registry is essential to the approval process. If the
registry does not work effectively, not enough data would be
gathered until the re-review period, and it would be necessary to
perform larger and longer trials in the initial review period. To in-
crease the feasibility of the management of the registry for PMDA,
collaboration with major academic societies and hospitals is
necessary to collect enough data in the post-marketing period. In
addition, continuous support from the national budget and indus-
trial consortiums becomes important to the sustainable manage-
ment of the registry.
Second, valid registries should be established for the natural
course and conventional treatment of the diseases in question to
strengthen the feasibility of single-arm studies. There are some
small registries for rare diseases in Japan, but they are not fully
validated for the review process. Validated data derived frommajor
registries may support conditional/time-limited authorization.
Third, the establishment of an objective committee to evaluate
effectiveness should be considered in the relevant academic soci-
ety. Data monitoring committees have the task to monitor the
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should be performed more objectively if single-arm or observa-
tional studies are utilized in the development of regenerative
medical products. If the human resource for objective evaluation is
limited, it may be appropriate to establish evaluating committees
from the academic arena related to the product under investigation.
The changes to the regulatory framework for regenerative
medical products may facilitate research and development and
contribute to the safety of regenerative medicine in Japan. The
framework may also be beneﬁcial to patients because it increases
the opportunity for them to receive a new treatment for an incur-
able disease while providing more information about safety and
efﬁcacy of the products. The appropriate management of this new
framework will ensure that Japan becomes an attractive venue for
the future development of regenerative medical products.
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